The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • The Antibody Society’s Committees
      • AIRR Community Committee
      • Communication & Membership Committee
      • Meetings Committee
    • Sponsors & Partners
  • Society meetings
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2023
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 2023
    • FOCIS Symposia
  • AIRR Community
    • AIRR News
    • AIRR Publications
    • AIRR Meetings
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-committees
      • Communications Sub-committee
      • Executive Sub-committee
      • Inferred Allele Review Committee
      • Meetings Sub-committee
    • AIRR Data Commons
    • AIRR Community Calendar
    • AIRR Community Webinar Series
    • On AIRR – An AIRR Community Podcast
    • AIRR Community Resources
    • AIRR Community Service Prize 2022
  • Members only
    • Login
    • Note to members
    • Member discount codes
    • 2023 Calendar of Events
    • James S. Huston Antibody Science Talent Award
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • JSH Award Criteria
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
    • Research Competitions
      • Research Competition Winners
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics
    • Adaptive Immune Receptor Repertoires
    • Antibody Discovery & Development
    • Commercializing Antibody Therapeutics
    • Antibodies to Watch
    • Antibody Validation
  • COVID-19
    • Guide to “Coronavirus in the Crosshairs”
    • COVID-19 Biologics Tracker
    • Meeting Report: The Diagnostic Landscape for COVID-19
You are here: Home / About / James S. Huston Antibody Science Talent Award / JSH Award Criteria

JSH Award Criteria

About the James S. Huston Antibody Science Talent Award:

The James S. Huston Antibody Science Talent Award is sponsored by The Antibody Society to recognize and encourage upcoming scientists in the field of Antibody Engineering and Therapeutics. Early career research scientists, i.e., those within 10 years of their most recent advanced degree (Ph.D., M.D., or equivalent), are eligible for the Award. The scientist is recognized for making important contributions to the antibody field and/or the dissemination of antibody knowledge. Eligibility of the nominee will be checked at time of nomination and before presentation of award. The recipient will be invited to give a lecture on their work, which will be made available on-line on The Antibody Society’s website.

The Award consists of: international recognition of the scientist’s accomplishments, a USD $1500 prize, and the travel costs and registration fee to attend the annual Antibody Engineering and Therapeutics conference in San Diego, California.

Applicants can be nominated by Members of The Antibody Society in good standing, which includes Members current on the Society’s annual dues, a student or post-doc eligible for a free membership or a Member eligible through the Society’s corporate sponsorship program.

Nominations will be accepted commencing June 15, 2023 and must be submitted by September 15, 2023. The winner will be selected by September 30th, and the Award will be presented in December.

Nomination process:

All documents should be sent as a single, combined PDF file to awards@antibodysociety.org. Please be aware that the single, combined PDF must be no larger than 20MB. Packages that are not complete will not be considered.

The nomination package should include the following:

  • At least one (1) nomination letter of not more than two (2) pages, signed and submitted by a Member of The Antibody Society in good standing, describing the Nominee’s qualifications for the award. The letter should address the Nominee’s ongoing contributions to the field of Antibody Engineering and Therapeutics and their potential for becoming an academic or industry leader. The letter should clearly highlight the scientific advance(s) and/or exceptional efforts in disseminating antibody knowledge in supporting the nomination.
  • Please include the Nominee’s complete contact information (full name [first, middle initial, last], title and affiliation, mailing address, phone number, and e-mail address). The nomination letter must be from one individual and should not include multiple endorsements within it. It should reflect the observations and opinions of the author. Please refrain from extensive reliance on quotations and observations of others.
  • An additional letter of recommendation of not more than two (2) pages may be included. The letter must be from one individual and should not include multiple endorsements within it. This letter must be signed and included in the package.
  • A curriculum vitae of the Nominee should be submitted including: education, year of PhD, MD or equivalent degree, postdoctoral experience, current affiliation and position, research interests, awards, service and/or knowledge dissemination to the scientific community, funding (if applicable) and relevant bibliography.

Nominations will be accepted commencing June 15, 2022. Complete nomination packages must be received by 11:59 PM Eastern time on September 15, 2022. Packages must be submitted by email as a single combined PDF file to awards@antibodysociety.org. Incomplete nomination packages or nominations that do not comply with the stated instructions will not be considered. The Antibody Society will not accept materials sent separately or through regular mail. Final award decisions will be at the discretion of The Antibody Society’s Board of Directors.

mabs

mabs

The Official Journal of The Antibody Society

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • FDA approves Zynyz™ (retifanlimab-dlwr) for Merkel cell carcinoma March 23, 2023
  • Ultralong CDR H3-based knobs: the smallest antibody fragment March 6, 2023
  • TRUST4 is now certified as AIRR-compliant March 1, 2023

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals